Linkage of cognitive impairments with metabolic disorders in schizophrenia

American Journal of Psychiatry

Volumn 167, Issue 10, 2010, Pages 1155-1157

  Nasrallah, Henry A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMPA RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DOPAMINE 1 RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT;

ANTIHYPERTENSIVE THERAPY; BODY MASS; COGNITIVE DEFECT; DIET THERAPY; DISEASE ASSOCIATION; GENETIC RISK; HUMAN; HYPERTENSION; INCREASED APPETITE; KINESIOTHERAPY; MEMORY; METABOLIC DISORDER; NOTE; OBESITY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SATIETY; SCHIZOPHRENIA; SIDE EFFECT; COMORBIDITY; DRUG DEVELOPMENT; METABOLIC SYNDROME X; PSYCHOLOGY;

ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; COMORBIDITY; DRUG DISCOVERY; HUMANS; METABOLIC DISEASES; METABOLIC SYNDROME X; OVERWEIGHT; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 77957956604     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2010.10060838     Document Type: Note

References (12)

1. Freedman R: Schizophrenia. N Engl J Med 2003; 349:1738-1749
2. Green MF: Stimulating the development of drug treatments to improve cognition in schizophrenia. Annu Rev Clin Psychol 2007; 3:159-180
3. Kraepelin E: Dementia Praecox and Paraphrenia (1919). Translated by Barclay RM; edited by Robertson GM. New York, Robert E Krieger, 1971
4. Meyer JM, Nasrallah HA: Medical Illness and Schizophrenia. Washington, DC, American Psychiatric Publishing, Inc, 2009
5. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Stroup TS, Lieberman JA: Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparisons with national estimates from NHANES III. Schizophr Res 2005; 80:19-32 (Pubitemid 41587460)
6. Coulton CW, Manderscheid RW: Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006; 31:1-4
7. Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, Lieberman JA: Low rates of treatment for hypertension, dyslipidemia, and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006; 86:15-22
8. Friedman JI, Wallenstein S, Moshier E, Parrella M, White L, Bowler S, Gottlieb S, Harvey PD, McGinn TG, Flanagan L, Davis KL: The effects of hypertension and body mass index on cognition in schizophrenia. Am J Psychiatry 2010; 167:1232-1239
9. Tamminga CA: The neurobiology of cognition in schizophrenia. J Clin Psychiatry 2006; 67(suppl 9):9-13
10. Sitskoorn MM, Aleman A, Ebisch SJ, Appels MC, Kahn RS: Cognitive deficits in relatives of patients with schizophrenia: a meta-analysis. Schizophr Res 2004; 71:285-295 (Pubitemid 39330506)
11. Vinogradov S, Fisher M, Warm H, Holland C, Kirshner MA, Pollock BG: The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry 2009; 166:1055-1062
12. Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, Rosenheck RA, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA: Change in metabolic syndrome with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from phase 1. Schizophr Res 2008; 101:273-286